08:00 , Jan 22, 2007 |  BioCentury  |  Strategy

Reset button

PDL BioPharma Inc. found itself caught between the hammer and the anvil in 2006, as revenue projections slipped while projected costs went up significantly. At the same time, a small product failed in Phase III,...
08:00 , Feb 2, 2004 |  BC Week In Review  |  Company News

Signet Laboratories Inc. management update

Signet Laboratories Inc. , Deadham, Mass.   Business: Diagnostic   Hired: Richard Gill as president and CEO, formerly president and CEO of Anvil Inc.; he replaces Ronald Casciato, who will remain as executive chairman  ...
08:00 , Jan 27, 2004 |  BC Extra  |  Company News

Signet hires Gill as CEO

Diagnostics company Signet (Deadham, Mass.) hired Richard Gill as president and CEO. Previously, he was president and CEO of Anvil. Gill replaces Ronald Casciato, who will remain as executive chairman....
08:00 , Mar 24, 2003 |  BC Week In Review  |  Company News

AnVil board of directors update

AnVil Inc. , Burlington, Mass.   Business: Bioinformatics   Appointed: Ronald Lindsay, CSO and VP of R&D at diaDexus Inc.  ...
08:00 , Feb 10, 2003 |  BC Week In Review  |  Company News

AnVil, National Cancer Institute deal

AnVil will use its informatics and data visualization capabilities to study NCI's databases of lung tumor gene expression in order to identify genes associated with the disease. AnVil Inc. , Burlington, Mass.   National Cancer...
08:00 , Nov 18, 2002 |  BC Week In Review  |  Company News

AnVil, ActiveCyte Holdings Inc. deal

AnVil licensed from ActiveCyte a hierarchical taxonomy of therapeutic areas and mechanisms of drug actions. AnVil will integrate the taxonomy into its analytical and visualization technologies, which can be used to explore data sets in...
08:00 , Nov 11, 2002 |  BC Week In Review  |  Company News

AnVil, Genomics Collaborative deal

The companies expanded an April deal to identify gene expression patterns in inflammatory disease, with an emphasis on rheumatoid arthritis, in order to discover therapeutic targets. As expanded, AnVil will use its informatics and data...
07:00 , Jun 17, 2002 |  BC Week In Review  |  Company News

Applied Biosystems Inc., AnVil deal

AnVil partnered with ABI to research the existence of "dark genes," which are genes predicted by computers that have not been confirmed. ABI will use a human genome DNA sequence from sister company Celera Genomics...
07:00 , Jun 12, 2002 |  BC Extra  |  Company News

AnVil, ABI gene identification deal

AnVil (Burlington, Mass.) partnered with Applied Biosystems (ABI) to research the existence of "dark genes," which are genes predicted by computers that have not been confirmed. ABI will use a human genome DNA sequence from...
07:00 , Apr 29, 2002 |  BC Week In Review  |  Company News

AnVil, Genomics Collaborative deal

AnVil will use its data analysis and visualization technologies to identify inflammatory disease-related gene expression patterns in microarray data from Genomics Collaborative. The main focus of the deal is rheumatoid arthritis. AnVil Inc. , Burlington,...